Description: ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Home Page: www.chromadex.com
10900 Wilshire Blvd
Los Angeles,
CA
90024
United States
Phone:
310 388 6706
Officers
Name | Title |
---|---|
Mr. Frank Louis Jaksch Jr. | Co-Founder & Chairman |
Mr. Robert N. Fried | CEO & Director |
Mr. Ozan Pamir C.F.A. | CFO & Principal Accounting Officer |
Dr. Andrew Shao Ph.D. | Senior Vice President of Global Regulatory & Scientific Affairs |
Mr. Carlos Lopez | Senior VP & General Counsel |
Alex Worsham | Vice President of Global Marketing & Communications |
Ms. Michiko Kelley | Chief Marketing Officer |
Ms. Chu Yan | Managing Director of Asia Pacific |
Kendall Knysch | Head of Media Relations & Partnerships |
Mr. James Lee | Controller |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 52.6316 |
---|---|
Trailing PE: | 322.5 |
Price-to-Book MRQ: | 15.1738 |
Price-to-Sales TTM: | 5.3745 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 106 |